TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19152905

Group type: EXPERIMENTAL
Intervention: Endoscopic therapies (including injection, thermocoagulation, clips)
Number of subjects: 4261

Group type: EXPERIMENTAL
Intervention: Injection alone
Number of subjects: 4261

Group type: EXPERIMENTAL
Intervention: Injection followed by thermal therapy
Number of subjects: 4261

Group type: EXPERIMENTAL
Intervention: Clips
Number of subjects: 4261

Group type: EXPERIMENTAL
Intervention: Surgery or mortality
Number of subjects: 4261

Group type: COMPARATOR
Intervention: Pharmacotherapy alone
Number of subjects: 4261
Study: 17573581

Group type: EXPERIMENTAL
Intervention: Tolvaptan (doses not specified)
Number of subjects: 319

Group type: COMPARATOR
Intervention: No intervention (placebo)
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Change in serum sodium (1 mmol/l increase)
Number of subjects: 319
Study: 16168813

Group type: EXPERIMENTAL
Intervention: Intracoronary radiation with rhenium-188-filled balloon system (17.6 Gy in 1.0-mm tissue depth)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Long-term follow-up of patients with dissections who had not undergone TVR
Number of subjects: 256
Study: 11999905

Group type: EXPERIMENTAL
Intervention: Valerian after 15 days of placebo trial post-BZD withdrawal
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo after 15 days post-BZD withdrawal
Number of subjects: 19

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 19
Study: 9951215

Group type: EXPERIMENTAL
Intervention: ADHD group
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study: 8547730

Group type: EXPERIMENTAL
Intervention: Albuterol (2 inhalations 4 times daily)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (2 inhalations 4 times daily)
Number of subjects: 10
Study: 2178398

Group type: EXPERIMENTAL
Intervention: PEG‐ELS 8 oz per day
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: PEG‐ELS 16 oz per day
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo 8 oz per day
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo 16 oz per day
Number of subjects: 32
Study: 375732

Group type: EXPERIMENTAL
Intervention: Cefazolin (Ancef), administered intravenously in a high-dose, short perioperative regimen
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Cefazolin (Ancef)
Number of subjects: 122
Study: 31498251

Group type: EXPERIMENTAL
Intervention: Simulation-based Korean Advanced Life Support (n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lecture-based education (n = 30)
Number of subjects: 60
Study: 31100332

Group type: EXPERIMENTAL
Intervention: Incremental filling (IF) with etch-and-rinse (ER)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Bulk-fill (BF) with etch-and-rinse (ER)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Incremental filling (IF) with self-etch (SE)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Bulk-fill (BF) with self-etch (SE)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Overall performance of BF technique
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Overall performance with ER strategy
Number of subjects: 72
Study: 27693404

Group type: EXPERIMENTAL
Intervention: Virtual reality associated with conventional physiotherapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (conventional physiotherapy only)
Number of subjects: 30
Study: 26304900

Group type: EXPERIMENTAL
Intervention: SCP care
Number of subjects: 221
Study: 23392634

Group type: COMPARATOR
Intervention: Whole Brain Radiotherapy (WBRT) 20 Gy
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Whole Brain Radiotherapy (WBRT) 30 Gy
Number of subjects: 113

Group type: COMPARATOR
Intervention: Best Supportive Care (BSC)
Number of subjects: 113
Study: 21529775

Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) plus clarithromycin (CLM) 500 mg b.i.d. for 3 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) plus clarithromycin (CLM)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) plus placebo
Number of subjects: 40
Study: 19122034

Group type: EXPERIMENTAL
Intervention: FTY720 1.25 mg/day
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: FTY720 5.0 mg/day
Number of subjects: 281

Group type: COMPARATOR
Intervention: Switch from placebo to FTY720
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Continuation of FTY720 treatment
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: FTY720 (both doses) after 24 months
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: FTY720
Number of subjects: 281
Study: 17508683

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bare metal stents
Number of subjects: 0
Study: 15138648

Group type: EXPERIMENTAL
Intervention: Proprioceptive function
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Visual and vestibular afferences
Number of subjects: 151
Study: 12370700

Group type: EXPERIMENTAL
Intervention: Daily pain management diary with nurse coaching regarding the pain management program
Number of subjects: 155

Group type: COMPARATOR
Intervention: Daily pain management diary for data collection
Number of subjects: 155
Study: 9874914

Group type: EXPERIMENTAL
Intervention: Forced smoking abstinence (smoking ban during BMT)
Number of subjects: 10136
Study: 7735515

Group type: EXPERIMENTAL
Intervention: Subcutaneous injections of a new, partially purified, characterized and standardized pollen extract of P. officinalis allergen (alum-absorbed depot preparation)
Number of subjects: 40
Study: 2525985

Group type: EXPERIMENTAL
Intervention: Etodolac (200 mg twice a day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Piroxicam (20 mg once a day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diclofenac (50 mg three times a day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Naproxen (500 mg twice a day)
Number of subjects: 0
Study: 124195

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Thymoxamine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Prostaglandin F2 alpha (PGF2 alpha)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (PGE2)
Number of subjects: 6
Study: 31706638

Group type: EXPERIMENTAL
Intervention: RUL‐UB ECT combined with Venlafaxine
Number of subjects: 240
Study: 31050763

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) + Care as Usual (CAU)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 70
Study: 28667080

Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation (300,000 IU)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 25586156

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 342

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 342
Study: 23607593

Group type: EXPERIMENTAL
Intervention: Sofosbuvir and ribavirin for 12 weeks
Number of subjects: 408

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Sofosbuvir and ribavirin for 16 weeks
Number of subjects: 408
Study: 21327911

Group type: EXPERIMENTAL
Intervention: Talniflumate (740 mg) with magnesium hydroxide (1 g)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Talniflumate (740 mg) without magnesium hydroxide
Number of subjects: 0
Study: 19961638

Group type: EXPERIMENTAL
Intervention: Hallway 6-minute walk test
Number of subjects: 19

Group type: COMPARATOR
Intervention: Treadmill 6-minute walk test
Number of subjects: 19
Study: 17377400

Group type: EXPERIMENTAL
Intervention: Sonography
Number of subjects: 31

Group type: COMPARATOR
Intervention: pH-monitoring
Number of subjects: 31
Study: 15529259

Group type: EXPERIMENTAL
Intervention: HAART
Number of subjects: 3496

Group type: COMPARATOR
Intervention: No TCF
Number of subjects: 3496

Group type: COMPARATOR
Intervention: TCF
Number of subjects: 3496
Study: 11855773

Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Stretch release relaxation
Number of subjects: 9

Group type: COMPARATOR
Intervention: Cognitive imagery relaxation
Number of subjects: 9
Study: 9831140

Group type: EXPERIMENTAL
Intervention: Standard preservation techniques (formaldehyde) for tympano-ossicular allograft preservation
Number of subjects: 5

Group type: COMPARATOR
Intervention: Nontreatment group (washed, dried, and stored in sterile tubes at -70 degrees without further processing)
Number of subjects: 5
Study: 8085587

Group type: EXPERIMENTAL
Intervention: Topical diclofenac sodium 0.1%
Number of subjects: 10

Group type: COMPARATOR
Intervention: Diclofenac vehicle
Number of subjects: 10
Study: 2486579

Group type: EXPERIMENTAL
Intervention: Intravenous meperidine 12.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous meperidine 25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Body-temperature epidural lidocaine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Room-temperature epidural lidocaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 0
Study: 7374

Group type: EXPERIMENTAL
Intervention: prazosin
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 30911113

Group type: EXPERIMENTAL
Intervention: Short telomere length
Number of subjects: 620
Study: 29185604

Group type: EXPERIMENTAL
Intervention: Periodontal therapy (PT)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no PT)
Number of subjects: 44
Study: 25865294

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 25
Study: 23819226

Group type: EXPERIMENTAL
Intervention: Moxibustion apparatus
Number of subjects: 100

Group type: COMPARATOR
Intervention: Routine treatment (2HRZE/4HRE)
Number of subjects: 100
Study: 21542675

Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 269

Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 269
Study: 19852040

Group type: EXPERIMENTAL
Intervention: 50 mg MMPD
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: 100 mg MMPD
Number of subjects: 354

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 354
Study: 16757129

Group type: COMPARATOR
Intervention: 68 Gy
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: 78 Gy
Number of subjects: 468
Study: 14740231

Group type: EXPERIMENTAL
Intervention: GSTM1 null genotype
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GSTT1 null genotype
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of GSTM1 and GSTT1 null genotypes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GSTP1 polymorphism
Number of subjects: 0
Study: 15629284

Group type: EXPERIMENTAL
Intervention: Pre-enucleation radiation
Number of subjects: 1003

Group type: COMPARATOR
Intervention: Enucleation alone
Number of subjects: 1003
Study: 10863964

Group type: EXPERIMENTAL
Intervention: IL‐1 genotype positive patients
Number of subjects: 323

Group type: COMPARATOR
Intervention: IL‐1 genotype negative patients
Number of subjects: 323

Group type: COMPARATOR
Intervention: IL‐1 genotype negative subjects
Number of subjects: 323
Study: 9197352

Group type: EXPERIMENTAL
Intervention: CMV disease
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Bacteremia
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Abdominal reexploration (excluding retransplantation)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Recipient age ≤ 16 years
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Number of units of blood products administered during transplantation
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Decreased pretransplant renal function (estimated by creatinine clearance)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Need for retransplantation
Number of subjects: 141
Study: 7968324

Group type: EXPERIMENTAL
Intervention: Intrathecal meperidine (0.2 mg/kg) with spinal tetracaine (12‐16 mg)
Number of subjects: 60
Study: 3512006

Group type: EXPERIMENTAL
Intervention: Hexabrix (sodium and meglumine ioxaglate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Meglumine iothalamate (ionic medium)
Number of subjects: 0
Study: 3142220

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 31903724

Group type: EXPERIMENTAL
Intervention: Insulin degludec/liraglutide (IDegLira)
Number of subjects: 1012

Group type: COMPARATOR
Intervention: Insulin glargine 100 units/mL (IGlar U100)
Number of subjects: 1012
Study: 30367884

Group type: EXPERIMENTAL
Intervention: Fluocinolone acetonide (FA) insert (0.18 mg)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 129
Study: 28963915

Group type: EXPERIMENTAL
Intervention: Subcutaneous trastuzumab (Herceptin® SC) 600 mg fixed dose followed by intravenous trastuzumab (Herceptin®) 8 mg/kg loading, 6 mg/kg maintenance doses every 3 weeks.
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Intravenous trastuzumab (Herceptin®) 8 mg/kg loading, 6 mg/kg maintenance doses every 3 weeks followed by subcutaneous trastuzumab (Herceptin® SC) 600 mg fixed dose.
Number of subjects: 488
Study: 25999771

Group type: EXPERIMENTAL
Intervention: Tailored neck muscle conditioning program (6-week exercise regime, performed 3 times a week)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (normal training and playing)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Tailored neck muscle conditioning program
Number of subjects: 34
Study: 22704520

Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal plain polysaccharide vaccine
Number of subjects: 0
Study: 20930212

Group type: EXPERIMENTAL
Intervention: Bilateral arm training with rhythmic auditory cueing (BATRAC)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Dose‐matched therapeutic exercises (DMTE)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: BATRAC
Number of subjects: 111
Study: 19321290

Group type: EXPERIMENTAL
Intervention: Chronic Disease Self‐Management Course (CDSMC)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Waiting‐List Control Group (WLCG)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Comparison Group (CG)
Number of subjects: 216
Study: 17141354

Group type: EXPERIMENTAL
Intervention: Insulin glargine and aspart
Number of subjects: 60

Group type: COMPARATOR
Intervention: NPH insulin and aspart
Number of subjects: 60
Study: 15099940

Group type: EXPERIMENTAL
Intervention: Selenium supplementation (200 microg, two capsules, four times daily)
Number of subjects: 31
Study: 11371744

Group type: EXPERIMENTAL
Intervention: Prospective randomized trials (PRTs)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Not enrolled in PRTs
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: PRTs
Number of subjects: 168
Study: 9811154

Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.025-0.4 mg/day
Number of subjects: 2700

Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.4 mg/day
Number of subjects: 2700

Group type: COMPARATOR
Intervention: Cerivastatin
Number of subjects: 2700
Study: 7915025

Group type: EXPERIMENTAL
Intervention: Dapiprazole
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (nontreated eyes)
Number of subjects: 30
Study: 3406455

Group type: EXPERIMENTAL
Intervention: Low energy neutrons alone
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Combined photon-low energy neutron treatment regimen (mixed beam)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: High energy neutrons alone
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Fast neutron radiotherapy (overall)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional photon and/or electron treatment
Number of subjects: 32
Study: 31782131

Group type: EXPERIMENTAL
Intervention: Dehydrated human amnion membrane (HAM) placed around the neurovascular bundle and vesicourethral anastomosis during radical prostatectomy.
Number of subjects: 328

Group type: COMPARATOR
Intervention: Placebo (control group).
Number of subjects: 328
Study: 30890552

Group type: EXPERIMENTAL
Intervention: 15 mg/kg siltuximab
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 27197603

Group type: EXPERIMENTAL
Intervention: Coping Power intervention delivered by teachers over a 6-month period
Number of subjects: 164

Group type: COMPARATOR
Intervention: Standard academic curriculum (Control)
Number of subjects: 164
Study: 26298296

Group type: EXPERIMENTAL
Intervention: HBV vaccination at 20 μg (for children < 10 years) or 40 μg (for children > 10 years) at time 0, 1, and 6 months.
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group received HBV vaccination at 10 μg (for children < 10 years) or 20 μg (for children > 10 years) at time 0, 1, and 6 months.
Number of subjects: 78
Study: 23371919

Group type: EXPERIMENTAL
Intervention: 0.1 mmol/kg gadobenate dimeglumine
Number of subjects: 68

Group type: COMPARATOR
Intervention: 0.2 mmol/kg gadopentetate dimeglumine
Number of subjects: 68
Study: 21600559

Group type: EXPERIMENTAL
Intervention: LESS cholecystectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard laparoscopic cholecystectomy (LC)
Number of subjects: 0
Study: 19366816

Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Best medical treatment
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Presence of ischemic skin lesions
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Presence of ulcerations or gangrene
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Radiological arterial disease score
Number of subjects: 120
Study: 16679934

Group type: EXPERIMENTAL
Intervention: Neutropenic diet
Number of subjects: 19

Group type: COMPARATOR
Intervention: FDA food safety guidelines
Number of subjects: 19
Study: 15286527

Group type: EXPERIMENTAL
Intervention: Low-fat vegan diet
Number of subjects: 59

Group type: COMPARATOR
Intervention: NCEP diet (National Cholesterol Education Program Step II)
Number of subjects: 59
Study: 11282756

Group type: EXPERIMENTAL
Intervention: Severe asthma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cystic fibrosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: COPD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mild asthma
Number of subjects: 0
Study: 9783191

Group type: EXPERIMENTAL
Intervention: CMA therapy for 4 weeks before LH-RH analogue injection
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: CMA therapy for 2 weeks before LH-RH analogue injection
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: CMA pretreatment
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: CMA therapy
Number of subjects: 44
Study: 7873847

Group type: EXPERIMENTAL
Intervention: Vertebral body autograft technique
Number of subjects: 46

Group type: COMPARATOR
Intervention: Modified Smith-Robinson technique
Number of subjects: 46
Study: 3416247

Group type: EXPERIMENTAL
Intervention: Bubbler oxygenating system
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Membrane oxygenating system
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood cardioplegia (Shiley-Buckberg system)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonoxygenated crystalloid cardioplegia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oxygenated crystalloid cardioplegia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Membrane and blood delivery systems
Number of subjects: 0
Study: 30680617

Group type: EXPERIMENTAL
Intervention: 6-month program of weekly aerobic exercises associated with nutritional counseling (n = 41)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Usual care with nutritional counseling (n = 20, one withdrawal)
Number of subjects: 61
Study: 28614869

Group type: EXPERIMENTAL
Intervention: MA212 (40 mL daily)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: MA212
Number of subjects: 92
Study: 26293069

Group type: EXPERIMENTAL
Intervention: Intravenous tramadol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Visual analog scale scores at rest
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Visual analog scale scores during coughing
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pethidine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Overall satisfaction degree
Number of subjects: 60
Study: 24163616

Group type: EXPERIMENTAL
Intervention: 20% HP
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 20% HP with light activation
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 20% HP with manganese gluconate
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 35% HP
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 35% HP with light activation
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 35% HP with manganese gluconate
Number of subjects: 120
Study: 21373969

Group type: EXPERIMENTAL
Intervention: Neoadjuvant temozolomide (TMZ) and 13‐cis retinoic acid (13‐cRA) treatment
Number of subjects: 32

Group type: COMPARATOR
Intervention: Retrospective comparison to TMZ-treated group in NOA-04 phase-III trial
Number of subjects: 32
Study: 19423623

Group type: EXPERIMENTAL
Intervention: Ultraviolet B phototherapy at home using a TL‐01 home phototherapy unit
Number of subjects: 196

Group type: COMPARATOR
Intervention: Standard narrowband ultraviolet B phototherapy in an outpatient setting
Number of subjects: 196
Study: 17344769

Group type: EXPERIMENTAL
Intervention: Antihypertensive medication adherence assessment via telephone questionnaire
Number of subjects: 295

Group type: COMPARATOR
Intervention: Age groups comparison
Number of subjects: 295

Group type: COMPARATOR
Intervention: Race and gender comparison
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Factors associated with poor adherence
Number of subjects: 295
Study: 15478486

Group type: EXPERIMENTAL
Intervention: Tunnel restoration with resin-based composites
Number of subjects: 38

Group type: COMPARATOR
Intervention: Class II resin-based composite restorations
Number of subjects: 38
Study: 11678747

Group type: EXPERIMENTAL
Intervention: Periprostatic local anaesthesia (LA)
Number of subjects: 157

Group type: COMPARATOR
Intervention: No anaesthesia
Number of subjects: 157